Ivantis
Ivantis is a medical device company that developed the Hydrus Microstent, a nitinol MIGS implant that scaffolds Schlemm's canal to lower intraocular pressure in adult primary open-angle glaucoma patients undergoing cataract surgery; acquired by Alcon in 2022.
- Company typePrivate
- Founded2007
- HeadquartersIrvine, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ivantis does
Ivantis is a clinical and commercial-stage medical device company that developed the Hydrus Microstent, a micro-invasive glaucoma surgery (MIGS) implant intended for adult patients with mild-to-moderate primary open-angle glaucoma undergoing cataract surgery. The Hydrus Microstent is an 8 mm nitinol scaffold designed to dilate and scaffold approximately 90 degrees of Schlemm's canal, restoring physiological aqueous outflow through the eye's natural drainage pathway rather than creating a synthetic bypass. The company monetizes through direct sales of the single-use implant to ophthalmic surgeons and ambulatory surgical centers, primarily in the United States with selected international markets reached prior to the Alcon transaction. Ivantis was founded in 2007 and is headquartered in Irvine, California; the FDA approval of Hydrus was secured in August 2018 on the strength of the HORIZON pivotal RCT (556 patients, with reported ~80% medication-free retention at five years and AAO's 2020 highest MIGS data quality rating). In 2022, Ivantis was acquired by Alcon and the Hydrus platform is now positioned within Alcon's surgical-vision portfolio alongside complementary phacoemulsification and selective laser trabeculoplasty systems, materially expanding its global distribution reach.
Ivantis firmographics
Firmographics- Name
- Ivantis
- Website
- https://ivantisinc.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Ivantis is a medical device company that developed the Hydrus Microstent, a nitinol MIGS implant that scaffolds Schlemm's canal to lower intraocular pressure in adult primary open-angle glaucoma patients undergoing cataract surgery; acquired by Alcon in 2022.
- Ownership category
- akta.pro rank
Ivantis industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty) (HLAHAJAI)
- akta.pro secondary industry
- Glaucoma Specialists (HLAKAKAG)
Keywords
Where Ivantis is headquartered
LocationHeadquarters
- HQ city
- Irvine
- HQ country
- United States
- HQ region
- North America
Markets served
Ivantis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Distribution channels2 records
Marketing channels4 records
Ivantis product offering
Product offeringCore offering
Ivantis developed and commercialized the Hydrus Microstent, a canal-based Microinvasive Glaucoma Surgery (MIGS) device made of nitinol (nickel-titanium alloy) that is approximately the size of an eyelash. The device spans approximately 90° of Schlemm's canal, dilating and scaffolding it to bypass the trabecular meshwork and restore aqueous humor outflow, reducing intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma undergoing cataract surgery.
Differentiator
Problem solved
Functional benefit
Products and services
- Hydrus® Microstent
Quantifiable outcome
- 59% of Hydrus Microstent patients remained medication-free at 5 years (n=308)
- +4 more outcomes
Companies that use Ivantis
Customer profileSegments1 record
Ideal customer profiles1 record
Ivantis technology and API
TechnologyTechnology focussed Yes
API detail
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Ivantis partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- AlconcoreIvantis developed and commercialized the Hydrus Microstent, a canal-based MIGS device for glaucoma surgery. Alcon acquired Ivantis in 2022 and now manufactures, markets, and distributes the Hydrus Microstent globally through its surgical ophthalmology channel. The acquisition provided Alcon with one of the most clinically validated MIGS devices and expanded its glaucoma portfolio. Alcon operates the MyAlcon Professional platform for ordering and customer management.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Ivantis competitors and assessment
Company assessmentBroad incumbents
- Alcon: Alcon is the global leader in ophthalmic surgery and acquired Ivantis in 2022. It now manufactures and distributes Hydrus through its surgical sales force and bundles it with Voyager DSLT, making it both the parent and a broad-incumbent channel/competitor for other MIGS devices.
- AbbVie (Allergan Aesthetics / Eye Care): AbbVie's Allergan franchise historically held the XEN Gel Stent MIGS asset. As a broad incumbent in ophthalmology and glaucoma pharmaceuticals, it competes with the Hydrus platform through alternative MIGS options and a large eye-care sales infrastructure.
- Carl Zeiss Meditec: Carl Zeiss Meditec is a broad incumbent in ophthalmic surgical equipment and diagnostics with glaucoma-relevant offerings (e.g., laser and imaging systems). It is a comparable peer through its surgical channel reach to the same glaucoma specialist customers.
- Bausch + Lomb: Bausch + Lomb is a broad ophthalmic incumbent with surgical, pharmaceutical, and contact lens franchises. It competes for surgeon mindshare and OR shelf space across glaucoma and adjacent ophthalmic surgical categories.
Direct peers
- Glaukos Corporation: Glaukos pioneered MIGS and is the dominant player with the iStent family of trabecular bypass stents. It is the most directly comparable peer to Ivantis/Hydrus, competing head-to-head in combined cataract-MIGS procedures for mild-to-moderate POAG.
- Sight Sciences: Sight Sciences commercializes the OMNI Surgical System, a MIGS device that combines trabeculotomy and viscodilation. It targets the same mild-to-moderate POAG segment as Hydrus and competes for surgeon adoption in combined and standalone MIGS procedures.
Emerging players
- MicroOptx: MicroOptx is developing the Beacon Aqueous Microshunt, an ab externo glaucoma drainage device. It is an emerging player in surgical glaucoma targeting a related but different mechanism, comparable to Ivantis as a glaucoma-focused medtech developer.
- iSTAR Medical: iSTAR Medical develops the MINIject supraciliary MIGS implant for glaucoma. It is an emerging MIGS player pursuing a different outflow pathway (suprachoroidal) but addressing the same POAG patient population as Hydrus.
- New World Medical: New World Medical manufactures the Kahook Dual Blade and other glaucoma surgical instruments. It is an emerging competitor in angle-based MIGS and ab interno procedures, overlapping with Hydrus's surgical glaucoma surgeon customer base.
- NovaEye Medical: NovaEye Medical develops the iTrack microcatheter for canaloplasty and ABiC procedures. It competes in the angle-based surgical glaucoma space and targets many of the same glaucoma surgeons as Hydrus.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Ivantis social profiles
Digital presenceIvantis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ivantis leadership team
Management profileNumber of profiles
Profiles8 records
Ivantis funding detail
Funding detailFunding overview
Funding rounds7 records
Investors16 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ivantis M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ivantis
What does Ivantis do?
Ivantis developed and commercialized the Hydrus Microstent, a canal-based Microinvasive Glaucoma Surgery (MIGS) device made of nitinol (nickel-titanium alloy) that is approximately the size of an eyelash. The device spans approximately 90° of Schlemm's canal, dilating and scaffolding it to bypass the trabecular meshwork and restore aqueous humor outflow, reducing intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma undergoing cataract surgery.
Is Ivantis a public or private company?
Ivantis is a private company. It is classified as corporate owned and is currently operating.
When was Ivantis founded?
Ivantis was founded in 2007. It employs 101 to 250 people.
Where is Ivantis based?
Ivantis is headquartered in Irvine, United States, in the North America region.
Who are Ivantis's main competitors?
Broad incumbents on record are Alcon, AbbVie (Allergan Aesthetics / Eye Care), Carl Zeiss Meditec and Bausch + Lomb. Direct peers are Glaukos Corporation and Sight Sciences. Emerging players are MicroOptx, iSTAR Medical, New World Medical and NovaEye Medical.
What industry is Ivantis in?
Ivantis's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAI, Glaucoma Diagnostics & Surgical Devices (Tonometry, Gonioscopy, MIGS, Drainage Implants, Laser Trabeculoplasty), with a secondary code of HLAKAKAG, Glaucoma Specialists. Its NAICS code is 334510 and its SIC code is 3841.